Physician profile
Christopher Mark White
NPI 1962935742
$8,735.99
in general payments reported to CMS, 2019-2025
31 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $145 · 2021: $513 · 2022: $1,466 · 2023: $2,360 · 2024: $1,867 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,366 · Education: $32.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,365.91 |
| Education | $32.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,956.17 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Lilly USA, LLC | $837.04 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $705.96 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $640.12 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $599.52 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $548.21 | 2021-2024 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $297.90 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $297.07 | 2022-2025 | |
| Galderma Laboratories, L.P. | $296.22 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $274.31 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $261.36 | 2022-2024 | Vtama |
| Genzyme Corporation | $251.37 | 2022-2025 | |
| Incyte Corporation | $242.04 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $233.73 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $213.32 | 2023-2025 | Jublia, Arazlo, Cabtreo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $148.24 | 2023-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $140.17 | 2019 | |
| Vyne Pharmaceuticals INC. | $111.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.98 | 2022-2024 | Spevigo, Cyltezo |
| Biofrontera INC. | $107.55 | 2024-2025 | Ameluz, Bf-Rhodoled, Rhodoled Xl |
| Pfizer INC. | $98.95 | 2022-2024 | |
| Journey Medical Corporation | $73.26 | 2022-2025 | |
| Organon LLC | $66.15 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $54.12 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $53.89 | 2023-2024 | Ycanth |
| Organogenesis INC. | $30.66 | 2025 | Novachor |
| Convatec INC. | $26.24 | 2025 | |
| Almirall LLC | $19.29 | 2022 | |
| Kerecis Limited | $17.64 | 2022 | |
| Allergan, INC. | $11.92 | 2022 | |
| Stemline Therapeutics INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.